Drug and Alcohol Dependence
September 12, 2025
Matthijs Blankers, Ruben Van Beek, Desirée Spronk et al.
1 citation
There is a lack of understanding of the nature of the post-acute affective response in the days after ecstasy/3,4-Methylenedioxymethamphetamine (MDMA) use and whether this is associated with ecstasy/MDMA use or circumstantial factors. In the three days following ecstasy/MDMA use, we evaluated whether a drop in mental well-being is observed and can be related to ecstasy use. Data for this study...
J Psychopharmacol
December 13, 2021
Ben Sessa, Jacob S. Aday, Steve O’Brien et al.
18 citations
BACKGROUND: Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy has shown promise in recent years for treating various mental health conditions, particularly those involving trauma. However, concerns about declines in mood and cognition during the days following dosing, also known as 'Blue Mondays', have been raised as limitations to its clinical use. Although...
medRxiv Preprint Server
December 7, 2020
Vasileia Kotoula, Argyris Stringaris, Nuria Mackes et al.
9 citations
preprint
Ketamine as an antidepressant improves anhedonia, a pernicious symptom of depression as early as 2h post-infusion. The effects of ketamine on anhedonia are thought to be exerted via actions on reward-related brain areas—yet, these actions remain largely unknown. This study examines ketamine’s effects during the anticipation and receipt of an expected reward, after the psychotomimetic effects of...
Behavioural Brain Research
August 17, 2020
Meryem Grabski, Anna Borissova, Beth Marsh et al.
Esketamine was recently licensed by the US Food and Drug Administration (FDA) and European Drug Agency (EDA) for use in treatment resistant depression (TRD), and further research indicates ketamine as a possible treatment in other mental health conditions. While the underlying mechanisms remain unclear, it has been hypothesised that ketamine's acute psychoactive effects may be associated with...
J Psychopharmacol
June 15, 2020
Anna Borissova, Bart Ferguson, Matthew B. Wall et al.
37 citations
BACKGROUND: 3,4-Methylenedioxymethamphetamine (MDMA) is being actively researched as an adjunct to psychotherapy. It may be beneficial to trust, empathy and cooperative behaviour due to its acute prosocial effects. AIM: To test (a) the acute effects of MDMA on measures of empathy, trust and cooperative behaviour, and (b) subacute changes in mood three days after MDMA administration. METHODS: =7...
Sci Rep
October 13, 2017
Robin Carhart-Harris, Leor Roseman, Mark Bolstridge et al.
590 citations
Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
March 2011
Yen F Tai, Rosa Hoshi, Catherine M Brignell et al.
Ecstasy (±3,4-methylenedioxymethamphetamine, MDMA) is a popular recreational drug with known serotonergic neurotoxicity. Its long-term effects on dopaminergic function are less certain. Studying the long-term effects of ecstasy is often confounded by concomitant polydrug use and the short duration of abstinence. We used (18)F-dopa positron emission tomography (PET) to investigate the long-term...
The British journal of psychiatry : the journal of mental science
October 2010
Celia J A Morgan, Gráinne Schäfer, Tom P Freeman et al.
The two main constituents of cannabis, cannabidiol and Δ(9)-tetrahydrocannabinol (THC), have opposing effects both pharmacologically and behaviourally when administered in the laboratory. Street cannabis is known to contain varying levels of each cannabinoid. To study how the varying levels of cannabidiol and THC have an impact on the acute effects of the drug in naturalistic settings. Cannabis...
Addiction (Abingdon, England)
January 2010
Celia J A Morgan, Leslie Muetzelfeldt, H Valerie Curran
'Recreational' use of ketamine is spreading rapidly among young people. In healthy individuals an acute dose of the N-methyl D-aspartate (NMDA) receptor antagonist ketamine induces marked psychosis-like effects and cognitive impairments, but little is known about the long-term effects of the drug. To evaluate the long-term neuropsychiatric or cognitive consequences. A total of 150 individuals...
Psychopharmacology
March 1, 2009
Mark Blagrove, Celia J. A. Morgan, H Valerie Curran et al.
Ketamine is an N-methyl-D: -aspartate (NMDA) receptor antagonist with psychotogenic effects and for which there are diverse reports of whether pleasant or unpleasant dreams result during anaesthesia, post-operatively or after sub-anaesthetic use. To assess in healthy volunteers the incidence of unpleasant dreams over the three nights after receiving a sub-anaesthetic dose of ketamine, in...
Psychopharmacology
October 2007
Rosa Hoshi, Kate Mullins, Catherine Boundy et al.
Despite years of research and much controversy surrounding the effects of ecstasy use, findings are equivocal. Attempting to reduce methodological problems, such as concurrent use of other recreational drugs, could lead to a clearer picture of the effects of ecstasy use on cognitive function. The aim of this study is to investigate the effects of both prolonged abstention from ecstasy use and...
Journal of psychopharmacology (Oxford, England)
March 2006
Rosa Hoshi, Hannah Pratt, Sachin Mehta et al.
The lowering of serotonin for a period following MDMA use could account for the increases in both self-rated and objective measures of aggression previously found in ecstasy users several days after taking the drug. There is some evidence of gender differences in the acute, sub-acute and long-term effects of MDMA use, and given that gender differences have been found in aggression, it is...